After National Bank and Mackie Research gave Knight Therapeutics (Other OTC: KHTRF) a Buy rating last month, the company received another Buy, this time from Bloom Burton. Analyst David Martin maintained a Buy rating on Knight Therapeutics yesterday and set a price target of C$8.00. The company’s shares closed last Monday at $4.09.
According to TipRanks.com, Martin is ranked #676 out of 7091 analysts.
Knight Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.52, a 34.5% upside from current levels. In a report issued on November 3, National Bank also maintained a Buy rating on the stock with a C$8.25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.00 and a one-year low of $3.44. Currently, Knight Therapeutics has an average volume of 6,159.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.